Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

377 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Assessment for the timing of comprehensive genomic profiling tests in patients with advanced solid cancers.
Hagio K, Kikuchi J, Takada K, Tanabe H, Sugiyama M, Ohhara Y, Amano T, Yuki S, Komatsu Y, Osawa T, Hatanaka KC, Hatanaka Y, Mitamura T, Yabe I, Matsuno Y, Manabe A, Sakurai A, Ishiguro A, Takahashi M, Yokouchi H, Naruse H, Mizukami Y, Dosaka-Akita H, Kinoshita I. Hagio K, et al. Among authors: kinoshita i. Cancer Sci. 2023 Aug;114(8):3385-3395. doi: 10.1111/cas.15837. Epub 2023 May 19. Cancer Sci. 2023. PMID: 37208840 Free PMC article.
EGFR inhibition in EGFR-mutant lung cancer cells perturbs innate immune signaling pathways in the tumor microenvironment.
Shiiya A, Noguchi T, Tomaru U, Ariga S, Takashima Y, Ohhara Y, Taguchi J, Takeuchi S, Shimizu Y, Kinoshita I, Koizumi T, Matsuno Y, Shinagawa N, Sakakibara-Konishi J, Dosaka-Akita H. Shiiya A, et al. Among authors: kinoshita i. Cancer Sci. 2023 Apr;114(4):1270-1283. doi: 10.1111/cas.15701. Epub 2022 Dec 26. Cancer Sci. 2023. PMID: 36529523 Free PMC article.
Early prediction of treatment outcome for lenvatinib using 18F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma refractory to radioiodine treatment: a prospective, multicentre, non-randomised study.
Takeuchi S, Hirata K, Magota K, Watanabe S, Moku R, Shiiya A, Taguchi J, Ariga S, Goda T, Ohhara Y, Noguchi T, Shimizu Y, Kinoshita I, Honma R, Tsuji Y, Homma A, Dosaka-Akita H. Takeuchi S, et al. Among authors: kinoshita i. EJNMMI Res. 2023 Jul 17;13(1):69. doi: 10.1186/s13550-023-01019-9. EJNMMI Res. 2023. PMID: 37460834 Free PMC article.
Clinical practice guidelines for molecular tumor markers, 2nd edition review part 1.
Kikuchi Y, Shimada H, Hatanaka Y, Kinoshita I, Ikarashi D, Nakatsura T, Kitano S, Naito Y, Tanaka T, Yamashita K, Oshima Y, Nanami T. Kikuchi Y, et al. Among authors: kinoshita i. Int J Clin Oncol. 2024 Jan;29(1):1-19. doi: 10.1007/s10147-023-02430-x. Epub 2023 Nov 29. Int J Clin Oncol. 2024. PMID: 38019341
LMNA::NTRK1 Fusion-positive Leiomyosarcoma: Discrepancy between DNA-based Comprehensive Genomic Profiling and RNA Sequencing.
Suzuki N, Idogawa M, Emori M, Murase K, Arihara Y, Nakamura H, Usami M, Kubo T, Kinoshita I, Sugita S, Tokino T, Hasegawa T, Sakurai A, Takada K. Suzuki N, et al. Among authors: kinoshita i. Intern Med. 2024 Aug 1;63(15):2215-2219. doi: 10.2169/internalmedicine.2879-23. Epub 2023 Dec 18. Intern Med. 2024. PMID: 38104989 Free PMC article.
Dabrafenib and trametinib administration in patients with BRAF V600E/R or non-V600 BRAF mutated advanced solid tumours (BELIEVE, NCCH1901): a multicentre, open-label, and single-arm phase II trial.
Shimoi T, Sunami K, Tahara M, Nishiwaki S, Tanaka S, Baba E, Kanai M, Kinoshita I, Shirota H, Hayashi H, Nishida N, Kubo T, Mamesaya N, Ando Y, Okita N, Shibata T, Nakamura K, Yamamoto N. Shimoi T, et al. Among authors: kinoshita i. EClinicalMedicine. 2024 Feb 2;69:102447. doi: 10.1016/j.eclinm.2024.102447. eCollection 2024 Mar. EClinicalMedicine. 2024. PMID: 38333370 Free PMC article.
377 results